Insider Buying: Vivani Medical (NASDAQ:VANI) Director Purchases 1,737,765 Shares of Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams acquired 1,737,765 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was purchased at an average price of $1.14 per share, with a total value of $1,981,052.10. Following the completion of the acquisition, the director directly owned 26,564,109 shares of the company’s stock, valued at $30,283,084.26. This represents a 7.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Gregg Williams also recently made the following trade(s):

• On Monday, December 15th, Gregg Williams acquired 1,737,765 shares of Vivani Medical stock. The shares were acquired at an average price of $1.14 per share, for a total transaction of $1,981,052.10.
• On Saturday, November 15th, Gregg Williams acquired 1,737,764 shares of Vivani Medical stock. The shares were acquired at an average cost of $1.14 per share, for a total transaction of $1,981,050.96.
• On Monday, October 27th, Gregg Williams bought 3,703,703 shares of Vivani Medical stock. The shares were bought at an average price of $1.62 per share, with a total value of $5,999,998.86.

Vivani Medical Trading Up 5.6%

Shares of NASDAQ:VANI traded up $0.07 on Tuesday, reaching $1.34. The company had a trading volume of 255,642 shares, compared to its average volume of 102,939. The firm has a market capitalization of $97.83 million, a PE ratio of -2.97 and a beta of 3.07. Vivani Medical, Inc. has a 52-week low of $0.91 and a 52-week high of $1.92. The firm’s 50 day simple moving average is $1.35 and its 200-day simple moving average is $1.39.

Vivani Medical (NASDAQ:VANI) last posted its earnings results on Thursday, November 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01. As a group, equities research analysts predict that Vivani Medical, Inc. will post -0.41 earnings per share for the current year.

Hedge Funds Weigh In On Vivani Medical

Several large investors have recently modified their holdings of VANI. Panagora Asset Management Inc. purchased a new position in Vivani Medical during the second quarter worth about $25,000. Citadel Advisors LLC purchased a new position in Vivani Medical in the third quarter valued at $26,000. Finally, Susquehanna International Group LLP grew its position in shares of Vivani Medical by 100.5% during the third quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after buying an additional 16,200 shares in the last quarter. Institutional investors and hedge funds own 6.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on VANI. Wall Street Zen upgraded Vivani Medical to a “sell” rating in a research note on Saturday, November 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, January 9th. Finally, Zacks Research raised shares of Vivani Medical from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 12th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Vivani Medical currently has a consensus rating of “Hold” and a consensus target price of $4.00.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.